According to the research of the pharmaceutical company IQVIAI, the Biocad biotechnology company became the leader in the sale of antitumor drugs in Russia’s pharmaceutical market. This was reported in Biocad press service.
Market experts, Pemboria (International Pembroralizumab ”) -It popular immuno -the first registered pinkrobrolyizumab and the infected portfolio expansion of the infected portfolio expansion.
According to Headway companies, the market volume of this drug in the hospital supply segment exceeded 19 million rubles in 2024.
In 2024, more than 50,000 people with various oncological diseases received treatment using Biocad drugs based on monoclonal antibodies with 64% more than 2023.
The company’s preparations are used in the treatment of lung cancer, melanoma, head and neck tumors, breast cancer, colorectal cancer and other malignant neoplasm treatment.
Biocad, the company’s III phase for the treatment of such oncological diseases seventeable melanoma, nipple gland, serous ovarian cancer and others recurrence or metastatic tripartite negative cancer continues to do clinical work, he said.
In January, the first fixed combination of monoclonal antibodies for the treatment of melanoma for the treatment of melanoma (unlodied “prolgolimab + nurulimab”) of the “Nurdati” medication (unseen “Nurdati”) is inserted into the updated list of vital and most important drugs. This expanded the access of Russian patients to modern therapy methods.
In addition, in 2024, more than 10,000 patients took drugs “Extrirastim”, which was 33% higher than the previous year. The drug is used to prevent neutropenia, which accompanies a critical decrease in the neutrophil level and increases the risk of serious infection.
What are you thinking?
Source: Gazeta

Ben Stock is a business analyst and writer for “Social Bites”. He offers insightful articles on the latest business news and developments, providing readers with a comprehensive understanding of the business world.